Trials / Completed
CompletedNCT00662025
Study Of Sunitinib With Capecitabine In Breast Cancer
A Phase II Study Of Sunitinib Malate In Combination With Capecitabine In Patients With Advanced Or Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Female
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate efficacy, safety and pharmacokinetics of sunitinib plus Capecitabine in Japanese patients with advanced/metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine | Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles |
| DRUG | Sunitinib | Sunitinib 37.5 mg daily, continuous dosing |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2009-12-01
- Completion
- 2012-05-01
- First posted
- 2008-04-21
- Last updated
- 2013-05-27
- Results posted
- 2010-10-13
Locations
17 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00662025. Inclusion in this directory is not an endorsement.